Answers are grounded in this paper and cite their sources.
Objective: Spinal tuberculosis (STB) remains a major clinical challenge in high-burden countries. Infection imaging agents such as [18F]FDG and [67Ga]Gallium citrate have limitations in specificity and interpretation. [68Ga]Gallium citrate, produced via a [68Ge/67Ga] generator, offers logistical and economic advantages. This prospective study evaluated the utility of [68Ga]Gallium citrate PET/CT for diagnosing active spinal TB and for treatment response assessment in comparison with [18F]FDG PET/CT. Methods: Thirty-two patients with suspected spinal TB underwent baseline [68Ga]Gallium citrate PET/CT and those with uptake in disease more than or equivalent to the uptake in the abdominal aorta were considered positive. All patients then received the standard anti-tubercular therapy (ATT). Follow-up imaging at 9–12 months included repeat [68Ga]Gallium citrate PET/CT (n = 21), of which 17 patients were also underwent [18F]FDG PET/CT. Lesions with SUVmax > 2.5 were considered metabolically active. Imaging findings were correlated with clinical outcomes. The uptake on functional imaging was correlated with other clinical, radiological, microbiological and histopathological data for each patient. Results: At baseline, 22/32 patients (68.8%) demonstrated increased [68Ga]Gallium uptake consistent with infective spondylodiscitis, while 10 (31.2%) showed no abnormal uptake. There was no statistically significant correlation between tracer uptake and clinical, radiological, or laboratory parameters. Follow-up imaging in 21 patients demonstrated complete resolution of increased [68Ga]Gallium uptake in all 12 baseline-positive cases and remained negative in 9 initially negative cases, correlating with symptomatic improvement. In contrast, [18F]FDG PET/CT performed in 17 patients showed persistent [18F]FDG avidity in 13 patients despite clinical remission, while 4 showed no abnormal uptake. Conclusion: Although [68Ga]Gallium citrate PET/CT does not appear to be a reliable diagnostic modality, it is useful in identifying active spinal TB and may serve as a reliable marker for therapeutic response in patients with baseline tracer uptake. Persistent [18F]FDG uptake despite clinical recovery indicates the limited specificity of [18F]FDG PET/CT for response assessment, likely reflecting residual inflammatory activity rather than active disease. Given its generator-based production and lower infrastructural requirements, [68Ga]Gallium citrate PET/CT may represent a cost-effective and accessible functional imaging modality for spinal TB, particularly in resource-limited settings with a high disease burden.
No takes yet. Share an insight, caveat, or question.
Varghese et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: